To date, MAPK-directed therapies have been successful in certain indications (i.e., BRAF V600E melanoma), encouraging in some (BRAF V600E colorectal cancer, KRAS G12C NSCLC), but have achieved only modest results in others. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.